144 related articles for article (PubMed ID: 30638910)
1. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy.
King MT; Nguyen PL; Boldbaatar N; Yang DD; Muralidhar V; Tempany CM; Cormack RA; Hurwitz MD; Suh WW; Pomerantz MM; D'Amico AV; Orio PF
Brachytherapy; 2019; 18(2):198-203. PubMed ID: 30638910
[TBL] [Abstract][Full Text] [Related]
2. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.
King MT; Nguyen PL; Boldbaatar N; Tempany CM; Cormack RA; Beard CJ; Hurwitz MD; Suh WW; D'Amico AV; Orio PF
Cancer; 2018 Sep; 124(17):3528-3535. PubMed ID: 29975404
[TBL] [Abstract][Full Text] [Related]
4. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
[TBL] [Abstract][Full Text] [Related]
5. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
6. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
7. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.
Nguyen PL; Chen MH; Zhang Y; Tempany CM; Cormack RA; Beard CJ; Hurwitz MD; Suh WW; D'Amico AV
J Urol; 2012 Oct; 188(4):1151-6. PubMed ID: 22901567
[TBL] [Abstract][Full Text] [Related]
8. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
9. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients.
Ko EC; Liu JT; Stone NN; Stock RG
Radiother Oncol; 2014 Feb; 110(2):261-7. PubMed ID: 24299969
[TBL] [Abstract][Full Text] [Related]
10. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
12. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.
Taussky D; Lambert C; Meissner N; Bahary JP; Delouya G
Brachytherapy; 2018; 17(5):794-798. PubMed ID: 30153914
[TBL] [Abstract][Full Text] [Related]
15. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
16. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
[TBL] [Abstract][Full Text] [Related]
17. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
18. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
19. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
